Study of hypokalemia and correlation with severity of disease in patients with COVID-19 positive severe acute respiratory illness and COVID-19 negative severe acute respiratory illness

Talavara Mahendra1*, Madhumathi R.1, Supriyaa Bhakthavatchalam B.2, Siddesh N. Nijaguna1

1Department of Internal Medicine, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India
2Department of Internal Medicine, Shri Atal Bihari Vajpayee Medical College and Research Institute, Bangalore, Karnataka, India

Received: 13 June 2021
Revised: 27 June 2021
Accepted: 28 June 2021

*Correspondence:
Dr. Talavara Mahendra,
E-mail: talavarmahendra2011@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Although the coronavirus disease-2019 (COVID-19) pandemic is creating a major global health crisis, the risk factors for mortality and the detailed clinical course of disease has not yet established. Clinical spectrum of the disease varies from mild symptoms to ARDS. The main objective of this study was to determine hypokalemia and correlation of severity of disease with hypokalemia in patients with COVID-19 positive SARI (severe acute respiratory illness) and COVID-19 negative SARI patients.

Methods: The study was a cross-sectional study conducted on 265 SARI patients who were admitted in hospitals attached to BMCRI from April 2019 to December 2019. History was taken, general and systemic examination was done. Patients were categorized and selected patients with moderate and severe illness. RT-PCR for COVID-19 patients done using throat and nasal swab. Potassium levels were estimated and correlated with severity of illness in patients with COVID-19 positive and COVID-19 negative status.

Results: The study included 265 SARI patients, of which 135 were COVID-19 positive patients and 130 were COVID-19 negative. Patients categorized into moderate and severe SARI. Mean age of subjects with COVID-19 positive (severe) was higher, 58.70±15.598 followed by COVID-19 positive (moderate), 55.13±14.480. About 30% (N=90) belonged to severe SARI group. Chi square test showed statistical significant association with respect to age. In this study there was no statistically significant hypokalemia found between COVID-19 positive SARI patients (N=20, 14.81%) and COVID-19 negative SARI patients (N=17, 13.07%). However hypokalemia COVID-19 positive SARI patients 14.81% (N=20) and COVID-19 negative SARI patients 13.07% (N=17). And also there is no statistically significant hypokalemia between SARI severe and SARI moderate cases.

Conclusions: However in this study there is no statistically significant hypokalemia found between COVID-19 positive SARI patients and COVID-19 negative SARI patients. And also there is not statistically significant hypokalemia between SARI severe and SARI moderate cases. Hypokalemia is found in both in both COVID-19 positive SARI patients and COVID-19 negative SARI patients and relatively more in COVID-19 positive patients. Hypokalemia is one of the treatable condition and early detection and treatment reduces mortality.

Keywords: SARI, COVID-19, Hypokalemia
INTRODUCTION

Since December 2019, a life-threatening coronavirus was recognized as the etiological factor of a series of severe pneumonia cases. COVID-19 is contagious disease spread through air droplet and aerosol. Spectrum of disease varies from mild influenza like illness to ARDS even may cause multiorgan dysfunction and death. Increased death was associated with old age and patients with comorbidities. COVID-19 virus invades human cells through binding angiotensin I converting enzyme 2 (ACE2) on the cell membrane. ACE2 is widely distributed in many types of human tissues, especially in the vital organs such as lungs liver, heart, kidney. ²

ACE2 is the principal counter-regulatory mechanism for the main axis of the rennin-angiotensin system (RAS), which is important in the control of blood pressure and electrolyte balance.³

COVID-19 virus binds ACE2 and enhances the degradation of ACE2 and thus decreases the counter-act of ACE2 on RAS. The final effect is to increase reabsorption of sodium and water, and thereafter increase blood pressure and excretion of potassium (K+).

Besides, patients with COVID-19 often had gastrointestinal symptoms such as vomiting and diarrhea. Collectively the impacts on RAS and gastrointestinal system by COVID-19 probably lead to disruptions of homeostasis of electrolytes and pH.³

Hypokalemia results in cellular hyperpolarity, increases resting potential and hastens depolarization in cardiac cells and lung cells and may cause arrhythmias and respiratory muscle paralysis. Hypokalemia is one of the life-threatening complication and should be monitored regularly to prevent mortality.⁴

Hypokalemia is one of the treatable condition and early detection and treatment reduces mortality.

Objective of our study was to correlate hypokalemia with severity of the disease in COVID-19 positive SARI and COVID-19 negative SARI patients.

METHODS

After obtaining institutional ethical committee clearance, cross-sectional study was conducted on 265 SARI patients who were admitted in hospitals attached to BMCRI from April 2019 to December 2019. History was taken, general physical examination and a detailed systemic examination was done. Patients were categorized into mild, moderate and severe illness according to WHO clinical criteria. RT-PCR for COVID-19 patients done using throat and nasal swab. Potassium levels were done and correlated with severity of COVID-19 positive and negative SARI.⁵

WHO criteria for categorizing the patients

Mild disease

Symptomatic patients with ILI symptoms without evidence of viral pneumonia or hypoxia were categorized as mild.

Moderate disease

Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnea, fast breathing) but no signs of severe pneumonia, including SpO2 ≥90% on room air were categorized as moderate.

Severe disease

Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnea, fast breathing) plus one of the following like respiratory rate >30 breaths/min, severe respiratory distress or SpO2 <90% on room air was categorized as severe.

Objectives

The objectives were to study hypokalemia in SARI patients and to correlate hypokalemia with severity of disease in SARI COVID-19 positive patients and SARI COVID-19 negative patients.

Type design

The study design was a cross-sectional study. The study was conducted from a period of April 2019 to December 2019. The study was conducted at the hospital attached to BMCRI.

Inclusion criteria

In-patients who were diagnosed with SARI, of either sex with age more than 18 years and willing to give informed consent were included.

Exclusion criteria

Patients not willing to give informed consent, age less than 18 years and on diuretics and/or diuretics were excluded.

Statistical method

Data was analyzed by descriptive statistics. Independent sample test was applied for quantitative variables between COVID-19 positive and COVID-19 negative subjects. Correlation between severity of COVID-19 infection and serum potassium levels was measured using Chi square test.
**Statistical analysis**

The statistical software used for data analysis were namely SAS 9.2, SPSS 15.0, Stata 10.1, MedCalc 9.0.1, Systat 12.0 and R environment ver.2.11.1 and Microsoft word and excel have been used to generate tables and graphs.

**RESULTS**

In this study, mean age of subjects with COVID-19 positive (severe) was higher, 58.70±15.598 followed by COVID-19 positive (moderate), 55.13±14.480 (Table 1).

In this study, distribution of the subjects was based on age. Subjects was higher above 65 years, 80 (30.2%) followed by age group of 36 to 45 years, 51 (19.2%). Chi square test was applied to associate the age with severity. Chi square test showed statistical significant association with respect to age (\( \chi^2=35.15; \ p=0.002 \)) (Table 2).

In this study distribution of the subjects based on gender. Males were higher, 174 (65.7%) as compared to females, 91 (34.3%). Chi square test was applied to associate the gender with severity. Chi square test showed no statistical significant association with respect to gender (\( \chi^2=3.16; \ p=0.78 \)) (Table 3).

| COVID-19 | Severity | N  | Minimum | Maximum | Mean | SD  |
|----------|----------|----|---------|---------|------|-----|
| Negative | Moderate | 69 | 20      | 86      | 46.90| 17.132|
|          | Severe   | 61 | 19      | 91      | 52.56| 15.988|
| Positive | Moderate | 54 | 25      | 80      | 55.13| 14.480|
|          | Severe   | 81 | 24      | 96      | 58.70| 15.598|

Table 1: Age distribution.

| Age (in years) | Negative | | | Positve | | | Total |
|----------------|----------|----------|----------|----------|----------|----------|----------|
|                | Moderate | Severe   | Moderate | Severe   |          |          |          |
| Less than 25   | Count    | 9        | 4        | 1        | 1        | 15       |
|                | %        | 13.0     | 6.6      | 1.9      | 1.2      | 5.7      |
| 26 to 35       | Count    | 9        | 5        | 5        | 7        | 26       |
|                | %        | 13.0     | 8.2      | 9.3      | 8.6      | 9.8      |
| 36 to 45       | Count    | 22       | 12       | 8        | 9        | 51       |
|                | %        | 31.9     | 19.7     | 14.8     | 11.1     | 19.2     |
| 46 to 55       | Count    | 7        | 13       | 13       | 11       | 44       |
|                | %        | 10.1     | 21.3     | 24.1     | 13.6     | 16.6     |
| 56 to 65       | Count    | 9        | 10       | 9        | 21       | 49       |
|                | %        | 13.0     | 16.4     | 16.7     | 25.9     | 18.5     |
| Above 65       | Count    | 13       | 17       | 18       | 32       | 80       |
|                | %        | 18.8     | 27.9     | 33.3     | 39.5     | 30.2     |
| Total          | Count    | 69       | 61       | 54       | 81       | 265      |
|                | %        | 100.0    | 100.0    | 100.0    | 100.0    | 100.0    |
| Chi square value=35.15  |
| P=0.002

Table 2: Distribution of age among the groups.

| Gender | Negative | | | Positve | | | Total |
|--------|----------|----------|----------|----------|----------|----------|----------|
|        | Moderate | Severe   | Moderate | Severe   |          |          |          |
| Female | Count    | 26       | 21       | 16       | 28       | 91       |
|        | %        | 37.7     | 34.4     | 29.6     | 34.6     | 34.3     |
| Male   | Count    | 43       | 40       | 38       | 53       | 174      |
|        | %        | 62.3     | 65.6     | 70.4     | 65.4     | 65.7     |
| Total  | Count    | 69       | 61       | 54       | 81       | 265      |
|        | %        | 100.0    | 100.0    | 100.0    | 100.0    | 100.0    |
| Chi square value=3.16  |
| P=0.78
Table 4: Distribution of subjects based on diabetes among the groups.

| Diabetes | Negative | | Positive | | Total |
|----------|----------|--------|----------|--------|--------|
|          | Moderate | Severe | Moderate | Severe |        |
| Nil      | Count    |        | %        |        |        |
|          | 56       | 37     | 26       | 47     | 166    |
| Present  | Count    |        | %        |        |        |
|          | 13       | 24     | 28       | 34     | 99     |
| Total    | Count    |        | %        |        |        |
|          | 69       | 61     | 54       | 81     | 265    |
| Chi square value=15.79  |
| P=0.001* |

*significant.

Table 5: Distribution of subjects based on HTN among the groups.

| HTN  | Negative | | Positive | | Total |
|------|----------|--------|----------|--------|--------|
|      | Moderate | Severe | Moderate | Severe |        |
| Nil  | Count    |        | %        |        |        |
|      | 47       | 30     | 38       | 48     | 163    |
| Present | Count |        | %        |        |        |
|        | 22       | 31     | 29.6     | 40.7   | 102    |
| Total | Count    |        | %        |        |        |
|        | 69       | 61     | 54       | 81     | 265    |
| Chi square value=7.15  |
| P=0.067 |

Table 6: Distribution of K+ levels.

| COVID-19 | Severity | N  | Minimum | Maximum | Mean | SD   |
|----------|----------|----|---------|---------|------|------|
| Negative | Moderate | 69 | 2.9     | 7.6     | 4.349| 0.8140|
|          | Severe   | 61 | 2.7     | 6.4     | 4.390| 0.8599|
| Positive | Moderate | 54 | 3.2     | 6.6     | 4.246| 0.6321|
|          | Severe   | 81 | 2.8     | 39.0    | 4.652| 3.9137|

Table 7: Groups using independent t test.

| Independent t test | COVID-19 negative versus COVID-19 positive |
|--------------------|--------------------------------------------|
|                    | Mean difference | P value |
| Potassium level    | 0.12            | 0.66    |

Table 8: Comparison between moderate and severe sub groups using independent sample t test.

| Comparison | Moderate versus severe |
|------------|------------------------|
| COVID-19 negative | Potassium level | -0.04 | 0.78 |
| COVID-19 positive  | Potassium level | -0.4 | 0.45 |

In this study out of 265 (100%) subjects, 99 (37.4%) had diabetes, out of which 34 (42%) were COVID-19 positive (severe) followed by 28 (51.9%) were COVID-19 positive (moderate). Chi square test was applied to associate the diabetes with severity. Chi square test showed statistical significant association with respect to diabetes ( \( \chi^2=15.79; p=0.001 \) ) (Table 4).

In this study of 265 (100%) subjects, 102 (38.5%) had hypertension, out of which 33 (40.7%) were COVID-19 positive (severe) followed by 31 (50.8%) were COVID-19 negative (severe). Chi square test was applied to associate the hypertension with severity. Chi square test showed no statistical significant association with respect to hypertension ( \( \chi^2= 7.15; p=0.067 \) ) (Table 5).
In this study mean K+ levels was higher in COVID-19 positive (severe) subjects, 4.65±3.91 followed by COVID-19 positive (moderate) subjects, 4.24±0.632 (Table 6). And independent sample t test showed there is no statistical significant difference potassium levels p=0.66 between COVID-19 positive and negative subjects (Table 7). And also independent sample t test showed there is no statistical significant difference between serum potassium level between COVID-19 negative and COVID-19 positive subjects (Table 8).

**DISCUSSION**

In our study demographic characteristics of the study subjects studied showed that males were higher as compared to females which was similar to 51.5% of patients were male in study conducted by Liu et al. Similar study was done by Mousavi-Nasab et al where 57.1% were males. Subjects taken were aged above 65 years, 80 (30.2%) followed by age group of 36 to 45 years, 51 (19.2%) with average age of 58.70±15. Similar study done by Liu et al showed average age was 62.1±14.6 years. We also studied distribution of diabetes and hypertension among the groups and out of 265 (100%) subjects, 99 (37.4%) had diabetes of which majority were severe COVID-19 positive. Association of diabetes with COVID-19 positive subjects was statistically significant.

102 patients had hypertension, which was more common with severe COVID-19 negative patients and then with severe COVID-19 positive patients, however association with hypertension was not statistically significant. Similar study done by Cheng et al showed that seventy-one patients (41%) had underlying diseases including hypertension (28 patients, 16%), diabetes (12 patients, 7%) and other conditions (31 patients, 18%).

Potassium plays an important role in maintaining normal cell function. K+ is the main intracellular cation and almost all cells have the pump called Na±K±ATPase which pumps sodium out of the cell and K+ into the cell leading to a K+ gradient across the cell membrane. If potassium balance is disrupted (hypokalemia or hyperkalemia), this can also lead to disruption of heart electrical conduction, dysrhythmias and even sudden death. The impact on RAS and gastrointestinal system by COVID-19 probably lead to disruptions of homeostasis of electrolytes and pH. Hypokalemia in cellular hyperpolarity, increases resting potential and hastens depolarization in cardiac cells and may cause arrhythmias. Previous studies have shown that significant changes in potassium are often associated with poor outcomes in many disease.

In this study there is no statistically significant hypokalemia found between COVID-19 positive SARI patients and COVID-19 negative SARI patients. And also there is no statistically significant hypokalemia between hypokalemia with SARI severe and SARI moderate cases. Similar study done by Liu et al showed patients with severe COVID-19 median baseline K+ level was 4.4. One more study done by Gelatino et al had mild severity of hypokalemia (90.7% had serum levels of K+ between 3.4 and 3 meq/l) and there is no associated mortality with hypokalemia in this group. Unlike other study done by Chen et al hypokalemia was prevalent among the patients with COVID-19, among 54% (95 of 175) of patients had plasma K+ less than 3.5 mmol/l.

**Limitations**

Association with mortality could not be established. As it was a cross sectional study, serial monitoring of potassium and correlation with the disease progression also could not be established. There were limited studies supporting hypokalemia in SARI patients.

**CONCLUSION**

However in this study there is not statistically significant hypokalemia found between COVID-19 positive SARI patients and COVID-19 negative SARI patients. And also there is not statistically significant hypokalemia between SARI severe and SARI moderate cases. Hypokalemia is found in both COVID-19 positive SARI patients and COVID-19 negative SARI patients and relatively higher in COVID-19 positive patients. Hence monitoring of serum potassium level is important in SARI patients and it is important to treat them to prevent mortality.

**Funding: No funding sources**

**Conflict of interest: None declared**

**Ethical approval: The study was approved by the Institutional Ethics Committee**

**REFERENCES**

1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
3. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, Goor HV. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;202(3):631-7.
4. Kardalas E, Paschou S, Anagnostis P, Muscogiuri G, Siasos G, Vryonidou A. Hypokalemia: a clinical update. Endocr Connec. 2018;7(4):135-46.
5. WHO. Fact sheet: Clinical management of COVID-19 patients: living guidance, 2021. Available at:
https://app.magicapp.org/#/guideline/j1WBYn/section/j2xMZn. Accessed on 29 May 2021.

6. Chen D, Li X, Song Q, Hu C, Su F, Dai J, et al. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China. JAMA Net Open. 2020;3(6):201112.

7. Zacchia M, Abategiovanni ML, Stratigis S, Capasso G. Potassium: from physiology to clinical implications. Kid Dis. 2016;2(2):72-9.

8. Tongyoo S, Viarasilpa T, Permpikul C. Serum potassium levels and outcomes in critically ill patients in the medical intensive care unit. J Int Med Res. 2018;46(3):1254-62.

9. Alfano G, Ferrari A, Fontana F, Perrone R, Mori G, Ascione E, et al. Hypokalemia in patients with COVID-19. Clinic Experiment Nephrol. 2021;25(4):401-9.

10. Liu S, Zhang L, Weng H, Yang F, Jin H, Fan F, et al. Association between average plasma potassium levels and 30-day mortality during hospitalization in patients with COVID-19 in Wuhan, China. Int J Med Sci. 2021;18(3):736-43.

11. Moreno-Pérez O, Leon-Ramirez J, Fuertes-Kenneally L, Perdiguero M, Andres M, Garcia-Navarro M, et al. Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: a case series of 306 Mediterranean patients. Int J Infect Dis. 2020;100:449-54.

Cite this article as: Mahendra T, Madhumathi R, Bhakthavatchalam BS, Nijaguna SN. Study of hypokalemia and correlation with severity of disease in patients with COVID-19 positive severe acute respiratory illness and COVID-19 negative severe acute respiratory illness. Int J Adv Med 2021;8:1102-7.